Morgan Keegan has published a research report following a positive notification from the data safety monitoring board that has given Baxter International, Inc. BAX the go-ahead to initiate a second Phase III study.
“We view the outcome of the futility analysis as encouraging, but note that the risks to a successful outcome remain significant. Accordingly, we remain conservative in our modeling and are not assuming any revenues associated with Alzheimer's Disease in our 10-year DCF. We maintain our Outperform rating and $60 price target,” Morgan Keegan commented in the report.
Baxter International, Inc. closed yesterday at $52.78.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in